Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799182 | 1.00 | PRCP (0.53) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL28967711 | 0.89 | PRCP (0.42) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL4354734 | 0.81 | PRCP (0.56) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL28762516 | 0.81 | PRCP (0.58) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL27808728 | 0.81 | PRCP (0.53) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL23285173 | 0.81 | PRCP (0.53) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL28252983 | 0.81 | PRCP (0.53) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL3087062 | 0.81 | CYP2D6 (0.38) | PRCPTSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL30435099 | 0.81 | CYP2D6 (0.38) | PRCPTSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL13281275 | 0.79 | PRCP (0.50) | PRCPGAATSHRNPSR1GID4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108534-A | Probes for Imaging Huntingtin | CHDI基金会股份有限公司 | 2017-08-29 | — | — | CN | claimed |
| CN-103703009-B | Noval chemical compound as diacylglycerol acyltransferase inhibitors | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2016-08-17 | — | — | CN | claimed |
| CN-103732596-A | Novel pyrrolopyrimidine derivatives | NOVARTIS AG | 2014-04-16 | — | — | CN | claimed |
| CN-102227409-B | Pyridine-3-carboxyamide derivative | KOWA CO | 2014-03-26 | — | — | CN | claimed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | claimed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | claimed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | claimed |
| CN-101668747-B | Tetrahydroisoquinolin-1-one derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-02-01 | — | — | CN | claimed |
| CN-101341129-B | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2011-12-14 | — | — | CN | claimed |
| CN-101068810-B | Carbostyril compound | OTSUKA PHARMA CO LTD | 2011-02-09 | — | — | CN | claimed |
| CN-101010299-A | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2007-08-01 | — | — | CN | claimed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | claimed |
| CN-1268636-C | Dolastatin 15 derivatives | ABSF AG (DE) | 2006-08-09 | — | — | CN | claimed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | claimed |
| US-20040138215-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| US-6617426-B1 | Peptide analogs of given formula; useful in treating neurodegenerative, autoimmune, cognitive disorders, stroke and traumatic injury | MERCK SHARP & DOHME CORP. | 2003-09-09 | — | — | US | claimed |
| CN-1264388-A | Dolastatin 15 derivatives | ABSF AG (DE) | 2000-08-23 | — | — | CN | claimed |
| US-5430041-A | Amino acid derivatives having antiviral activity | HOFFMANN-LA ROCHE INC. (US) | 1995-07-04 | — | — | US | claimed |
| EP-0401676-B1 | Enzyme inhibitors | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1995-01-11 | — | — | EP | claimed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138215-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | PRCP 87/4885GAA 228/4885TSHR 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.